Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 392-400

  Sun, Chia Chi ^a   Vaja, Valentina ^a,b   Babitt, Jodie L ^a   Lin, Herbert Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AB12B9M; ADENYLATE KINASE; ANTIFERROPORTIN MONOCLONAL ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; IRON; LDN 193189; LIPOCALIN; MONOCLONAL ANTIBODY; NOX H94; OLIGONUCLEOTIDE; PRS 80; RECOMBINANT ERYTHROPOIETIN; SHORT HAIRPIN RNA; SMAD4 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D;

ANEMIA; ANEMIA OF CHRONIC DISEASE; BLOOD TRANSFUSION; CELL SURFACE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIET THERAPY; DRUG MEGADOSE; ERYTHROPOIESIS; GENE SILENCING; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; INFECTION RISK; INFLAMMATION; IRON ABSORPTION; IRON BALANCE; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; OXYGENATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; TREATMENT PLANNING; TUMOR GROWTH; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANEMIA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMICROBIAL CATIONIC PEPTIDES; BONE MORPHOGENETIC PROTEIN 6; CATION TRANSPORT PROTEINS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GPI-LINKED PROTEINS; HOMEOSTASIS; HUMANS; INFLAMMATION; INTERLEUKIN-6; IRON; MICE; MOLECULAR TARGETED THERAPY; PYRAZOLES; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; STAT3 TRANSCRIPTION FACTOR; THERAPIES, INVESTIGATIONAL; VITAMIN D;

EID: 84862792124     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23110     Document Type: Review

References (160)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
2. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3(4): 235-375.
3. Locke A, Main ER, Rosbash DO. The copper and non-hemoglobinous iron contents of the blood serum in disease. J Clin Invest 1932; 11: 527-542.
4. Andrews NC. Anemia of inflammation: The cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-1253.
5. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788.
6. Ganz T. The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. Isr Med Assoc J 2002; 41: 1043-1045.
7. Nemeth E, Rivera S, Gabayan V. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
8. Roy CN, Mak HH, Akpan I. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007; 109: 4038-4044.
9. Nemeth E, Tuttle MS, Powelson J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
10. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009; 46: 387-393.
11. McCord JM. Iron, free radicals, and oxidative injury. J Nutr 2004; 134: 3171S-3172S.
12. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008; 8: 1-3.
13. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306: 1520-1528.
14. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-4433.
15. Ramey G, Deschemin JC, Durel B. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica 2010; 95: 501-504.
16. De Domenico I, Ward DM, Langelier C. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007; 18: 2569-2578.
17. Tanno T, Bhanu NV, Oneal PA. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
18. Tanno T, Porayette P, Sripichai O. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181-186.
19. Nicolas G, Chauvet C, Viatte L. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
20. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008; 7: 28-32.
21. Hentze MW, Muckenthaler MU, Galy B. Two to tango: Regulation of mammalian iron metabolism. Cell 2010; 142: 24-38.
22. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol 2009; 4: 489-515.
23. Cartwright GE, Lauritsen MA, Jones PJ. The anemia of infection. I. Hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J Clin Invest 1946; 25: 65-80.
24. Ganz T. Hepcidin-A peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 2006; 306: 183-198.
25. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr 2010; 30: 105-122.
26. Theurl I, Aigner E, Theurl M. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood 2009; 113: 5277-5286.
27. Nicolas G, Bennoun M, Porteu A. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-4601.
28. Rivera S, Liu L, Nemeth E. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005; 105: 1797-1802.
29. Weinstein DA, Roy CN, Fleming MD. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100: 3776-3781.
30. Feder JN, Gnirke A, Thomas W. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
31. Camaschella C, Roetto A, Cali A. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
32. Papanikolaou G, Samuels ME, Ludwig EH. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
33. Roetto A, Papanikolaou G, Politou M. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22.
34. Gao J, Chen J, Kramer M. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009; 9: 217-227.
35. Schmidt PJ, Andrews NC, Fleming MD. Hepcidin induction by transgenic overexpression of Hfe does not require the Hfe cytoplasmic tail, but does require hemojuvelin. Blood 2010; 116: 5679-5687.
36. Schmidt PJ, Toran PT, Giannetti AM. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008; 7: 205-214.
37. Pietrangelo A. Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139: 393-408, 408:e1-e2.
38. Andriopoulos BJr, Corradini E, Xia Y. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487.
39. Babitt JL, Huang FW, Wrighting DM. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539.
40. Meynard D, Kautz L, Darnaud V. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478-481.
41. Corradini E, Babitt JL, Lin HY. The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev 2009; 20: 389-398.
42. Babitt JL, Huang FW, Xia Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117: 1933-1939.
43. Truksa J, Lee P, Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 2009; 113: 688-695.
44. Truksa J, Peng H, Lee P. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol 2007; 139: 138-147.
45. Truksa J, Lee P, Beutler E. The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: Lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood Cells Mol Dis 2007; 39: 255-262.
46. Wang RH, Li C, Xu X. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409.
47. Xia Y, Babitt JL, Sidis Y. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008; 111: 5195-5204.
48. Steinbicker AU, Bartnikas TB, Lohmeyer LK. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011; 118: 4224-4230.
49. Ganz T, Olbina G, Girelli D. Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-4297.
50. Kemna E, Pickkers P, Nemeth E. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1866.
51. Lee P, Peng H, Gelbart T. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-1910.
52. Sakamori R, Takehara T, Tatsumi T. STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo. J Gastroenterol 2010; 45: 244-248.
53. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204-3209.
54. Verga Falzacappa MV, Casanovas G, Hentze MW. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med 2008; 86: 531-540.
55. Verga Falzacappa MV, Vujic Spasic M, Kessler R. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109: 353-358.
56. Fleming RE, Hepcidin activation during inflammation: Make it STAT. Gastroenterology 2007; 132: 447-449.
57. Huang H, Constante M, Layoun A. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 2009; 113: 3593-3599.
58. Yu PB, Hong CC, Sachidanandan C. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4: 33-41.
59. Brown WS, Marsh JT, Wolcott D. Cognitive function, mood and P3 latency: Effects of the amelioration of anemia in dialysis patients. Neuropsychologia 1991; 29: 35-45.
60. Mancuso A, Migliorino M, De Santis S. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 2006; 17: 146-150.
61. Felker GM, Adams KF, Jr, Gattis WA. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-966.
62. Zamboni V, Cesari M, Zuccala G. Anemia and cognitive performance in hospitalized older patients: Results from the GIFA study. Int J Geriatr Psychiatry 2006; 21: 529-534.
63. McClellan WM, Flanders WD, Langston RD. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 2002; 13: 1928-1936.
64. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-342.
65. Littlewood TJ, Bajetta E, Nortier JW. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
66. Swaak A. Anemia of chronic disease in patients with rheumatoid arthritis: Aspects of prevalence, outcome, diagnosis, and the effect of treatment on disease activity. J Rheumatol 2006; 33: 1467-1468.
67. FDA. Drugs@FDA: Epogen/Procrit FDA. Application #: (BLA) 103234; 1989. Available from: Accessed on 3 November, 2011.
68. Gandra SR, Finkelstein FO, Bennett AV. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am J Kidney Dis 2010; 55: 519-534.
69. FDA. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp; 2/26/ 2010. Available from:. Accessed on 27 October, 2011.
70. Pettersson T, Rosenlof K, Friman C. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scand J Rheumatol 1993; 22: 188-193.
71. Hertel J, Locay H, Scarlata D. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: Results from simplify the treatment of anemia with Aranesp (STAAR). Am J Nephrol 2006; 26: 149-156.
72. Ludwig H, Rai K, Blade J. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematol J 2002; 3: 121-130.
73. Adamson JW. The anemia of inflammation/malignancy: Mechanisms and management. Hematol Am Soc Hematol Educ Program 2008(no. 1): 159-165.
74. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741.
75. Pfeffer MA, Burdmann EA, Chen CY. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
76. Singh AK, Szczech L, Tang KL. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
77. Bohlius J, Schmidlin K, Brillant C. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
78. Bennett CL, Silver SM, Djulbegovic B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008; 299: 914-924.
79. Smith REJr, Aapro MS, Ludwig H. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-1050.
80. Leyland-Jones B, Semiglazov V, Pawlicki M. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005; 23: 5960-5972.
81. Epogen® (Epoetin Alfa) Injection, for Intravenous or Subcutaneous Use [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2011.
82. Aranesp® (Darbepoetin Alfa) Injection, for Intravenous or Subcutaneous Use [package insert], Thousand Oaks, CA: Amgen, Inc.; 2011.
83. Zaritsky J, Young B, Wang HJ. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056.
84. Fudin R, Jaichenko J, Shostak A. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 1998; 79: 299-305.
85. Macdougall IC, Tucker B, Thompson J. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699.
86. Markowitz GS, Kahn GA, Feingold RE. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48: 34-40.
87. Coyne DW, Kapoian T, Suki W. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984.
88. Henry DH, Dahl NV, Auerbach M. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
89. Hedenus M, Birgegard G, Nasman P. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007; 21: 627-632.
90. Kapoian T, O'Mara NB, Singh AK. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379.
91. Steensma DP, Sloan JA, Dakhil SR. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29: 97-105.
92. Steensma DP, Sasu BJ, Sloan JA, et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial.J Clin Oncol 29: 2011 (suppl; abstr 9031).
93. Ashby DR, Gale DP, Busbridge M. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981.
94. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1( Suppl 1): S19-S23.
95. Drueke TB, Massy ZA. Intravenous iron: How much is too much? J Am Soc Nephrol 2005; 16: 2833-2835.
96. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother 2007; 41: 1476-1480.
97. Canziani ME, Yumiya ST, Rangel EB. Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment. Artif Organs 2001; 25: 866-869.
98. Sazawal S, Black RE, Ramsan M. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 2006; 367: 133-143.
99. Daoud E, Nakhla E, Sharma R. Q: Is iron therapy for anemia harmful in the setting of infection? Cleve Clin J Med 2011; 78: 168-170.
100. Leavy O. Therapeutic antibodies: Past, present and future. Nat Rev Immunol 2010; 10: 297.
101. Sasu BJ, Cooke KS, Arvedson TL. Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115: 3616-3624.
102. Xiao JJ, Krzyzanski W, Wang YM. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 2010; 12: 646-657.
103. Leung DDM, Swanson BA, Tang Y, Luan P, Witcher DR. Anti-Hepcidin Antibodies and Uses Thereof. Patent # 7820163. Indianapolis, IN: Eli Lilly and Company; 2011.
104. Lily. Clinical Development Pipeline; 2011. Available from:. Accessed on 14 October, 2011.
105. Alnylam Pharmaceuticals. ALN-HPN: Refractory Anemia; 2011. Available from:. Accessed on 27 September, 2011.
106. Wang J, Lu Z, Wientjes MG. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J 2010; 12: 492-503.
107. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007; 117: 3623-3632.
108. Xenon, Isis and Xenon Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin; 2010. Available from: http://www.xenon-pharma. com/2010/11/isis-and-xenon-collaborate-to-develop-antisense-drugs-agains t-hemojuvelin-and-hepcidin/. Accessed on 28 September, 2011.
109. Graham MJ, Crooke ST, Monteith DK. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1998; 286: 447-458.
110. Flower DR. The lipocalin protein family: Structure and function. Biochem J 1996; 318(Pt. 1): 1-14.
111. Schlehuber S, Skerra A. Lipocalins in drug discovery: From natural ligand-binding proteins to "anticalins". Drug Discov Today 2005; 10: 23-33.
112. Hohlbaum A, Trentmann S, Gille H, et al., Podium #92. Exploiting lipocalin biochemistry for the treatment of anemia: Discovery and characterization of an anti-hepcidin therapeutic. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011), May 22-26, 2011. Vancouver, BC, Canada Am J Hematol 2011;86(9). Hohlbaum A, Trentmann S, Gille H Am J Hematol 2011; 86: E48.
113. Pieris. Preclinical Pipeline PRS-080; 10/19. 2011. Available from:. Accessed on 3 November, 2011.
114. Vater A, Klussmann S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Discov Devel 2003; 6: 253-261.
115. Pendergrast PS, Marsh HN, Grate D. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech 2005; 16: 224-234.
116. Noxxon. NOX-H94; 2011. Available from:. Accessed on 17 October, 2011.
117. Schwoebel F, Sell S, Maasch C, et al. Podium #91. NOX-H94, In vitro and in vivo characterization of a hepcidin blocking spiegelmer. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011) May 22-26, 2011. Vancouver, BC, Canada: Am J Hematol 2011;86(9):E47 Schwoebel F, Sell S, Maasch C Am J Hematol 2011; 86: E47.
118. Maasch C, Vater A, Buchner K. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J Biol Chem 2010; 285: 40012-40018.
119. Kulkarni O, Eulberg D, Selve N. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther 2009; 328: 371-377.
120. Ninichuk V, Clauss S, Kulkarni O. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008; 172: 628-637.
121. Bilik KU, Erguven E, Klussmann S. In-vitro and in-vivo antagonistic action of an anti-amylin Spiegelmer. Neuroreport 2007; 18: 1855-1859.
122. Kulkarni O, Pawar RD, Purschke W. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18: 2350-2358.
123. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-257.
124. Bragdon B, Moseychuk O, Saldanha S. Bone morphogenetic proteins: A critical review. Cell Signal 2011; 23: 609-620.
125. Camaschella C. BMP6 orchestrates iron metabolism. Nat Genet 2009; 41: 386-388.
126. Solloway MJ, Dudley AT, Bikoff EK. Mice lacking Bmp6 function. Dev Genet 1998; 22: 321-339.
127. Zhou G, Myers R, Li Y. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
128. Cuny GD, Yu PB, Laha JK. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 2008; 18: 4388-4392.
129. Yu PB, Deng DY, Lai CS. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008; 14: 1363-1369.
130. Theurl I, Schroll A, Sonnweber T. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic disease in rats. Blood 2011.
131. Steinbicker AU, Sachidanandan C, Vonner AJ. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011; 117: 4915-4923.
132. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal 2011; 23: 1831-1842.
133. Corradini E, Schmidt PJ, Meynard D. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 2010; 139: 1721-1729.
134. Gitelman SE, Kobrin M, Lee A. Structure and sequence of the mouse Bmp6 gene. Mamm Genome 1997; 8: 212-214.
135. Poli M, Girelli D, Campostrini N. Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011; 117: 997-1004.
136. Walenga JM, Frenkel EP, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Hematol Oncol Clin North Am 2003; 17: 259-282, viii-ix.
137. Ohtake T, Saito H, Hosoki Y. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res 2007; 31( 1 Suppl): S2-S8.
138. Gerjevic LN, Liu N, Lu S. Alcohol activates TGF-beta but inhibits BMP receptor-mediated smad signaling and Smad4 binding to hepcidin promoter in the liver. Int J Hepatol 2012; 2012: 459278.
139. Harrison-Findik DD. Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease? World J Gastroenterol 2009; 15: 1186-1193.
140. Song SN, Tomosugi N, Kawabata H. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116: 3627-3634.
141. Hashizume M, Uchiyama Y, Horai N. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 2010; 30: 917-923.
142. van Rhee F, Fayad L, Voorhees P. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28: 3701-3708.
143. Lang VR, Englbrecht M, Rech J. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 2011.
144. Edwards CJ. IL-6 inhibition and infection: Treating patients with tocilizumab. Rheumatology (2011) doi: 10.1093/rheumatology/ker311.
145. Caceres-Cortes JR. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem 2008; 8: 717-722.
146. Turkson J, Ryan D, Kim JS. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276: 45443-45455.
147. Zhang X, Yue P, Fletcher S. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 2010; 79: 1398-1409.
148. Fatih N, Camberlein E, Island ML. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med 2010; 88: 477-486.
149. Holick MF. The cutaneous photosynthesis of previtamin D3: A unique photoendocrine system. J Invest Dermatol 1981; 77: 51-58.
150. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320: 980-991.
151. Perlstein TS, Pande R, Berliner N. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: Association with anemia of inflammation. Blood 2011; 117: 2800-2806.
152. Saab G, Young DO, Gincherman Y. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138.
153. Kumar VA, Kujubu DA, Sim JJ. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol 2011; 24: 98-105.
154. Lac PT, Choi K, Liu IA. The effects of changing vitamin D levels on anemia in chronic kidney disease patients: A retrospective cohort review. Clin Nephrol 2010; 74: 25-32.
155. Bacchetta J, Zaritsky J, Lisse TS, et al. Poster #FR-PO1560. Vitamin D as a new regulator of iron metabolism: Vitamin D suppresses hepcidin in vitro and in vivo. J Am Soc Nephrol 2011; 22: 474A.
156. Aucella F, Scalzulli RP, Gatta G. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract 2003; 95: c121-c127.
157. Panichi V, De Pietro S, Andreini B. Calcitriol modulates in vivo and in vitro cytokine production: A role for intracellular calcium. Kidney Int 1998; 54: 1463-1469.
158. Fernandes A, Preza GC, Phung Y. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009; 114: 437-443.
159. Fung E, Hsu J, Damoiseaux R, et al. Poster #198. High throughput screen identifies two classes of small molecules as hepcidin antagonists. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011) May 22-26, 2011. Vancouver, BC, Canada. Am J Hematol 2011;86(9):E140 Fung E, J.H., Damoiseaux R Am J Hematol 2011; 86: E140.
160. Leung DDM, Luan P, Menetta JV, Tang Y, Witcher D. Anti-Ferroportin 1 Monoclonal Antibodies and Uses Thereof. International Patent # PCT/US2009/066187. Indianapolis, IN: Eli Lily and Company; 2010.